Excellent Results Received From GeoVax’s Full-Dose HIV/AIDS Vaccine Trial

GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced today excellent safety and immunogenicity data from its full-dose HIV/AIDS vaccine human trial which began in September 2006. This full-dose trial is the second in a series of four Phase 1 human trials designed to test the safety and immunogenicity of the GeoVax HIV/AIDS vaccines. [click link for full article]

More: continued here

Filed under: HIV / AIDS on November 4th, 2007